BIOMAY OBTAINS FDA APPROVAL FOR MANUFACTURING OF CAS9 NUCLEASE AT HEADQUARTERS SITE

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Biomay AG

Logo

Images

News Aktuell associated0

Tags

Pharmaceutical

Health

More Like This

BIOMAY LAUNCHES FDA-GRADE CRISPR/CAS9 NUCLEASE FOR OFF-THE-SHELF PURCHASE

PR Newswire associated0

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

NAYO to Announce the Launch of Fully Automated Biobanking Solutions in Europe at Medica 2024